<SEC-DOCUMENT>0001144204-18-056795.txt : 20181101
<SEC-HEADER>0001144204-18-056795.hdr.sgml : 20181101
<ACCEPTANCE-DATETIME>20181101160200
ACCESSION NUMBER:		0001144204-18-056795
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20181101
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20181101
DATE AS OF CHANGE:		20181101

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Lipocine Inc.
		CENTRAL INDEX KEY:			0001535955
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				990370688
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36357
		FILM NUMBER:		181153629

	BUSINESS ADDRESS:	
		STREET 1:		675 ARAPEEN DRIVE, SUITE 202
		CITY:			SALT LAKE CITY
		STATE:			X1
		ZIP:			84108
		BUSINESS PHONE:		801 994 7383

	MAIL ADDRESS:	
		STREET 1:		675 ARAPEEN DRIVE, SUITE 202
		CITY:			SALT LAKE CITY
		STATE:			X1
		ZIP:			84108

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MARATHON BAR CORP
		DATE OF NAME CHANGE:	20111130
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tv505906_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">UNITED STATES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SECURITIES AND EXCHANGE COMMISSION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">WASHINGTON, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">FORM 8-K</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CURRENT REPORT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Pursuant to Section 13 or 15(d) of</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The Securities Exchange Act of 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of Earliest Event Reported):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>November 1, 2018</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_002.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>LIPOCINE INC.&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Commission File No. 001-36357</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Delaware</FONT></TD>
    <TD STYLE="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 39%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">99-0370688</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">(State or other jurisdiction of incorporation)</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">(IRS Employer Identification Number)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>675 Arapeen Drive, Suite 202</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Salt Lake City, Utah 84108</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices)
(Zip Code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&rsquo;s telephone number, including
area code: <B>(801) 994-7383</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Former name or former address, if changed
since last report: <B>Not Applicable</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">______________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Wingdings">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Wingdings">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Wingdings">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Wingdings">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933&nbsp;(17 CFR &sect; 230.405) or&nbsp;Rule 12b-2 of the Securities
Exchange Act of 1934&nbsp;(17 CFR &sect; 240.12b-2).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to&nbsp;Section 13(a) of the Exchange Act. <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%"><B>Item&nbsp;8.01</B></TD>
    <TD STYLE="width: 92%"><B>Other Events</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On November 1, 2018, Lipocine Inc. issued a press release announcing
completion of enrollment in the ambulatory blood pressure study for TLANDO&trade;. The press release is filed as Exhibit 99.1 and
are incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%"><B>Item&nbsp;9.01</B></TD>
    <TD STYLE="width: 92%"><B>Financial Statements and Exhibits.</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>



<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exhibits</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following exhibits are filed with this report:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 19%; border-bottom: Black 1pt solid; padding-right: 0; padding-bottom: 12pt; padding-left: 0"><FONT STYLE="font-size: 10pt"><U>Exhibit No.&#9;</U></FONT></TD>
    <TD STYLE="width: 81%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><U>Description</U></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P><A HREF="tv505906_ex99-1.htm" STYLE="-sec-extract: exhibit">99.1</A></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P><A HREF="tv505906_ex99-1.htm" STYLE="-sec-extract: exhibit">Press Release Announcing the Completion of Enrollment in the Ambulatory Blood Pressure Study for TLANDO&trade;</A></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 85.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 85.5pt"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 85.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SIGNATURES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">LIPOCINE INC.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="width: 32%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="width: 11%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="width: 6%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="width: 43%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">November 1, 2018</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">/s/ Mahesh V. Patel</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Mahesh V. Patel</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">President and Chief Executive Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; background-color: white"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tv505906_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; background-color: white"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #333333"><B>Lipocine Announces Completion
of Enrollment in Ambulatory Blood Pressure Study for TLANDO&trade;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white; color: #333333"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>SALT LAKE CITY, UT</B>, November 1, 2018 &ndash; Lipocine
Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced the completion of enrollment in the ambulatory blood pressure
(&ldquo;ABPM&rdquo;) clinical study for TLANDO&trade;, the Company's oral testosterone product candidate for testosterone replacement
therapy (&quot;TRT&quot;) in adult males for conditions associated with a deficiency of endogenous testosterone, also known as
hypogonadism. This study is being conducted to definitively characterize TLANDO&rsquo;s blood pressure increase effect, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;We are pleased to have completed enrollment in the ABPM
study for TLANDO, which is expected to provide data in the first quarter of 2019, and look forward to bringing TLANDO to patients,&quot;
said Dr. Mahesh Patel, Chairman, President and Chief Executive Officer of Lipocine. &ldquo;Across our 52-week SOAR Phase 3 clinical
trial, TLANDO did not show a mean increase at any time point (i.e., 3 weeks, 7 weeks, 13 weeks, 26 weeks, 39 weeks, 52 weeks) using
office visit cuff blood pressure measurements with the proposed market dosing regimen.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>About Lipocine</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Lipocine Inc.
is a specialty pharmaceutical company developing innovative pharmaceutical products for use in men's and women's health using its
proprietary drug delivery technologies. Lipocine's clinical development pipeline includes four development programs TLANDO, LPCN
1144, LPCN 1111 and LPCN 1107. &nbsp;TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate, is designed
to help restore normal testosterone levels in hypogonadal men. TLANDO&nbsp;received a Complete Response Letter from the FDA on
May 8, 2018.&nbsp;LPCN 1144, an oral prodrug of bioidentical testosterone, is being developed as a treatment of non-alcoholic steatohepatitis
(&ldquo;NASH&rdquo;) and is currently being studied in two proof-of-concept clinical studies. LPCN 1111, a novel oral prodrug of
testosterone, originated and is being developed by Lipocine as a next-generation oral testosterone product with potential for once-daily
dosing and is currently in Phase 2 testing.&nbsp; LPCN 1107 is potentially the first oral hydroxyprogesterone caproate product
candidate indicated for the prevention of recurrent preterm birth and has been granted orphan drug designation by the FDA. An End
of Phase 2 meeting with the FDA has been completed. For more information, please visit&nbsp;www.lipocine.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Forward-Looking
Statements </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">This release contains
&ldquo;forward looking statements&rdquo; that are made pursuant to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995 and include statements that are not historical facts regarding Lipocine&rsquo;s product candidates and related
clinical trials and the FDA review process relating to its product candidates, the timing of completion of clinical trials including
the ABPM study for TLANDO, the path to approvability by the FDA of Lipocine&rsquo;s development programs, the potential uses and
benefits of our product candidates, and our product development efforts. Investors are cautioned that all such forward-looking
statements involve risks and uncertainties, including, without limitation, the risks that the FDA will not approve any of our products,
risks related to our products, expected product benefits not being realized, clinical and regulatory expectations and plans not
being realized, new regulatory developments and requirements, risks related to the FDA approval process including the receipt of
regulatory approvals, the results and timing of clinical trials, patient acceptance of Lipocine&rsquo;s products, the manufacturing
and commercialization of Lipocine&rsquo;s products, and other risks detailed in Lipocine&rsquo;s filings with the SEC, including,
without limitation, its Form 10-K and other reports on Forms 8-K and 10-Q, all of which can be obtained on the SEC website at www.sec.gov.
Lipocine assumes no obligation to update or revise publicly any forward-looking statements contained in this release, except as
required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">CONTACT:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Morgan Brown</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Executive Vice President &amp; Chief Financial
Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Phone: (801) 994-7383</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; color: blue"><U>mb@lipocine.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Investors:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Hans Vitzhum</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Phone: (646) 597-6979</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">hans@lifesciadvisors.com&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; background-color: white"><B>&nbsp;</B></P>





</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !* 0(# 2(  A$! Q$!_\0
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MV%[_ %/Y&L"&V^*?B(?:5FU*%&Y!\\6H_!05_E7<^ /AU:>'K2+4-2A2;5G
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M_P!&1U[S7S)X&\5IX/UN;4)+1KH26S0;%?9C+*V<X/\ =_6O0?\ A>5M_P!
M&7_P)'_Q- 'K5>&?&[_D9M/_ .O/_P!G:MG_ (7E;?\ 0!E_\"1_\36#\8YQ
M=:UI%P%VB73U?;G.,LQQ0!O?&7_D6=#_ .NA_P#0!7>>"?\ D1]$_P"O./\
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M1^&K'6]+0G4+=IUDA!P+J+SG)0_[0ZJ>Q^M:7P^N$N]&U"YC#!)=3N)%##!
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1**'*Z"%-1;:ZA1114FA__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
